Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells 4,179 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard Prins sold 4,179 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the sale, the director directly owned 35,183 shares in the company, valued at approximately $953,459.30. This represents a 10.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Amphastar Pharmaceuticals Stock Up 3.7%

NASDAQ:AMPH traded up $0.98 during trading hours on Tuesday, hitting $27.69. The company’s stock had a trading volume of 375,501 shares, compared to its average volume of 536,484. Amphastar Pharmaceuticals, Inc. has a 52-week low of $20.39 and a 52-week high of $46.11. The stock has a market capitalization of $1.27 billion, a P/E ratio of 10.37 and a beta of 0.77. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The stock has a fifty day moving average of $25.62 and a 200-day moving average of $25.46.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, November 6th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 18.64% and a return on equity of 20.76%. The business had revenue of $191.84 million for the quarter, compared to analysts’ expectations of $186.90 million. On average, equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on AMPH shares. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Piper Sandler dropped their price target on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday. Needham & Company LLC cut their target price on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Bank of America lifted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $31.20.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently modified their holdings of the company. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 20.2% in the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock valued at $64,130,000 after purchasing an additional 371,856 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Amphastar Pharmaceuticals by 7.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,755,665 shares of the company’s stock valued at $46,789,000 after buying an additional 128,781 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in shares of Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock worth $36,632,000 after buying an additional 130,672 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in shares of Amphastar Pharmaceuticals by 14.5% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock worth $36,565,000 after buying an additional 160,034 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock worth $22,348,000 after buying an additional 18,161 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.